Large randomized phase III trials conducted in patients with non-small-cell lung cancer (NSCLC) harboring activating mutations in EGFR have demonstrated that erlotinib or gefitinib are superior to platinum-based chemotherapy. Zhou et al. have now confirmed that these agents represent the best treatment we can offer today as front-line therapy for EGFR-mutant NSCLC.boxed-text
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective
Health Economics Review Open Access 26 June 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Zhou, C. C. et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12, 735–742 (2011).
Gridelli, C. et al. International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line E in advanced non-small cell lung cancer (aNSCLC): The TORCH trial [abstract]. J. Clin. Oncol. 28 (Suppl. 15), a7508 (2010).
Giaccone, G. et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin. Cancer Res. 12, 6049–6055 (2006).
Thomas, M. et al. Innovations: Randomized phase II trial of erlotinib (E)/bevacizumab (B) compared with cisplatin (P)/gemcitabine (G) plus B in first-line treatment of advanced nonsquamous (NS) non-small cell lung cancer (NSCLC) [abstract]. J. Clin. Oncol. 29 (Suppl. 15), a7504 (2011).
Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500 (2004).
Lee, J. S. et al. A randomized phase III study of gefitinib (IRESSA™) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung [abstract PRS4]. J. Thor. Oncol. 4, S283–S284 (2009).
Mok, T. S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947–957 (2009).
Maemondo, M. et al. Gefitinib or chemotherapy for non small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362, 2380–2388 (2010).
Mitsudomi, T. et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11, 121–128 (2010).
Rosell, R. et al. Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European erlotinib versus chemotherapy (EURTAC) phase III randomized trial [abstract]. J. Clin. Oncol. 29 (Suppl. 15), a7503 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
F. Cappuzzo receives honoraria from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Roche and he owns a patent on EGFR testing using fluorescence in situ hybridization. L. Landi declares no competing interests.
Rights and permissions
About this article
Cite this article
Landi, L., Cappuzzo, F. Front-line therapy in lung cancer with mutations in EGFR. Nat Rev Clin Oncol 8, 571–573 (2011). https://doi.org/10.1038/nrclinonc.2011.135
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2011.135
This article is cited by
-
Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective
Health Economics Review (2021)